Open Access

RESIDENT’S CORNER

Management of a patient with locally advanced prostate cancer with degarelix: a case report

Vladimir Ruzhynsky, Paul Whelan

Division of Urology, McMaster Institute of Urology, Department of Surgery, McMaster University, Hamilton, Ontario, Canada
Address correspondence to Dr. Vladimir Ruzhynsky, Department of Surgery, McMaster University, 1280 Main Street West, Hamilton, Ontario L8S 4L8 Canada

Canadian Journal of Urology 2013, 20(3), 6808-6810.

Abstract

Gonadotropin releasing hormone (GnRH) antagonists, such as degarelix, are emerging as an androgen deprivation therapy primary agents in a treatment of advanced prostate cancer. The role of GnRH antagonists in management of lower urinary tract symptoms associated with prostate cancer has not been clearly established. In this report, we describe the case of a patient with locally advanced prostate cancer who presented with symptoms of urinary retention and renal failure. The use of degarelix in this patient led to a rapid reduction in the prostate-specific antigen level; however, obstructive symptoms persisted despite the use of degarelix and radiation treatment.

---

Keywords

---